FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912455502> ?p ?o ?g. }

• W2912455502 endingPage "1708" @default.
• W2912455502 startingPage "1708" @default.
• W2912455502 abstract "Abstract [Introduction] Neuron-specific enolase (NSE) is the γ-γ or γ-δ dimer isoenzyme of enolase, an acidic protease that promotes the conversion of β-glycerophosphate into dihydroxyacetone phosphate during glycolysis, is mainly found in mature neurons and cells of neuronal origin. Studies of NSE as a tumor marker have primarily focused on patients with small cell lung cancer and neuroblastoma. NSE is not only a useful marker for disease aggressiveness, but also a prognostic factor. Elevated serum NSE expression has been found in 35% of non-neuroendocrine tumors, such as non-small cell lung carcinoma, breast cancer, and multiple myeloma. However, few reports have indicated whether serum NSE levels influence the clinical features and prognosis of malignant lymphoma (ML). In this study, we analyzed the serum NSE levels of patients with newly diagnosed ML and investigated their correlation with clinical outcomes. [Methods] We retrospectively analyzed 187 patients with ML diagnosed at our institution between 2011 and 2017. The patients included 109 males and 78 females with a median age of 72 years (range 22-93 years). The histological subtypes were; 93 DLBCL, 42 FL, 9 MALT, 7 MCL, 5 BL, 12 PTCL, 12 HL, and others. The study protocol was approved by the Institutional Review Board of Yokohama Municipal Citizen's Hospital, and it was carried out in accordance with the Declaration of Helsinki. [Results] Median follow-up time was 38 months. The mean serum value of NSE in 187 lymphoma patients was 23.77+/- 36.04 ng/ml. The mean NSE value in 93 DLBCL patients was significantly higher than that in 42 FL patients (26.99+/-27.56 ng/ml versus 13.80+/-6.85 ng/ml, respectively; p=0.003). Among 93 DLBCL patients, the optimal serum NSE cutoff value for predicting 3-year survival was determined by ROC analysis to be 17.1 ng/ml. In DLBCL patients, patients with high serum NSE levels (≥17.1 ng/ml; N=40) had significantly shorter overall survival (OS) than those with low serum NSE levels (<17.1 ng/ml; N=53) (3-year OS, 29.2% versus 70.9%, respectively; p<0.001) (Figure 1). In univariate analysis, parameters having adverse significance for OS were: high serum NSE levels, high serum LDH levels, PS≥2, stage 3-4, and R-IPI poor risk. In multivariate analysis, parameters having independent adverse significance for OS were: high serum NSE levels (≥17.1 ng/ml) (p=0.03, HR 2.04) and PS≥2 (p<0.001, HR 4.82). Among 42 FL patients, patients with high serum NSE levels (N=10) had also shorter OS than those with low serum NSE levels (N=32) (3-year OS, 60.0% versus 85.1%, respectively; p=0.02). The mean NSE value in high-risk FLIPI patients was higher than that in low- or intermediate-risk FLIPI patients (19.36+/-12.02 ng/ml versus 11.89+/-2.44 ng/ml, respectively; p=0.002). [Conclusion] In the present study we demonstrated that serum NSE levels were elevated in patients with various types of lymphoma. In particular, our data proved that a high serum NSE level is an independent prognostic factor for survival in patients with DLBCL. These results suggest that serum NSE levels at diagnosis may have an important role in malignant lymphoma and also may be a useful prognostic biomarker. Since our results are based on a small-sized analysis, further large prospective studies are warranted to verify this conclusion. Disclosures No relevant conflicts of interest to declare." @default.
• W2912455502 created "2019-02-21" @default.
• W2912455502 creator A5022095843 @default.
• W2912455502 creator A5062083888 @default.
• W2912455502 creator A5070130441 @default.
• W2912455502 creator A5078858702 @default.
• W2912455502 creator A5080861620 @default.
• W2912455502 creator A5083981865 @default.
• W2912455502 creator A5090513773 @default.
• W2912455502 date "2018-11-29" @default.
• W2912455502 modified "2023-09-30" @default.
• W2912455502 title "Prognostic Significance of Neuron-Specific Enolase in Patients with Malignant Lymphoma" @default.
• W2912455502 doi "https://doi.org/10.1182/blood-2018-99-113986" @default.
• W2912455502 hasPublicationYear "2018" @default.
• W2912455502 type Work @default.
• W2912455502 sameAs 2912455502 @default.
• W2912455502 citedByCount "0" @default.
• W2912455502 crossrefType "journal-article" @default.
• W2912455502 hasAuthorship W2912455502A5022095843 @default.
• W2912455502 hasAuthorship W2912455502A5062083888 @default.
• W2912455502 hasAuthorship W2912455502A5070130441 @default.
• W2912455502 hasAuthorship W2912455502A5078858702 @default.
• W2912455502 hasAuthorship W2912455502A5080861620 @default.
• W2912455502 hasAuthorship W2912455502A5083981865 @default.
• W2912455502 hasAuthorship W2912455502A5090513773 @default.
• W2912455502 hasBestOaLocation W29124555021 @default.
• W2912455502 hasConcept C126322002 @default.
• W2912455502 hasConcept C142724271 @default.
• W2912455502 hasConcept C143998085 @default.
• W2912455502 hasConcept C188618488 @default.
• W2912455502 hasConcept C204232928 @default.
• W2912455502 hasConcept C2776256026 @default.
• W2912455502 hasConcept C2779338263 @default.
• W2912455502 hasConcept C63363279 @default.
• W2912455502 hasConcept C71924100 @default.
• W2912455502 hasConcept C77231918 @default.
• W2912455502 hasConcept C90924648 @default.
• W2912455502 hasConceptScore W2912455502C126322002 @default.
• W2912455502 hasConceptScore W2912455502C142724271 @default.
• W2912455502 hasConceptScore W2912455502C143998085 @default.
• W2912455502 hasConceptScore W2912455502C188618488 @default.
• W2912455502 hasConceptScore W2912455502C204232928 @default.
• W2912455502 hasConceptScore W2912455502C2776256026 @default.
• W2912455502 hasConceptScore W2912455502C2779338263 @default.
• W2912455502 hasConceptScore W2912455502C63363279 @default.
• W2912455502 hasConceptScore W2912455502C71924100 @default.
• W2912455502 hasConceptScore W2912455502C77231918 @default.
• W2912455502 hasConceptScore W2912455502C90924648 @default.
• W2912455502 hasIssue "Supplement 1" @default.
• W2912455502 hasLocation W29124555021 @default.
• W2912455502 hasOpenAccess W2912455502 @default.
• W2912455502 hasPrimaryLocation W29124555021 @default.
• W2912455502 hasRelatedWork W2053551177 @default.
• W2912455502 hasRelatedWork W2057941175 @default.
• W2912455502 hasRelatedWork W2071092698 @default.
• W2912455502 hasRelatedWork W2152276557 @default.
• W2912455502 hasRelatedWork W2285926448 @default.
• W2912455502 hasRelatedWork W2321860123 @default.
• W2912455502 hasRelatedWork W2397016644 @default.
• W2912455502 hasRelatedWork W2410581036 @default.
• W2912455502 hasRelatedWork W42304180 @default.
• W2912455502 hasRelatedWork W91050093 @default.
• W2912455502 hasVolume "132" @default.
• W2912455502 isParatext "false" @default.
• W2912455502 isRetracted "false" @default.
• W2912455502 magId "2912455502" @default.
• W2912455502 workType "article" @default.